JP4750690B2 - 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用 - Google Patents

創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用 Download PDF

Info

Publication number
JP4750690B2
JP4750690B2 JP2006502781A JP2006502781A JP4750690B2 JP 4750690 B2 JP4750690 B2 JP 4750690B2 JP 2006502781 A JP2006502781 A JP 2006502781A JP 2006502781 A JP2006502781 A JP 2006502781A JP 4750690 B2 JP4750690 B2 JP 4750690B2
Authority
JP
Japan
Prior art keywords
peptide
seq
cells
wound
hcap18
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006502781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006518375A5 (https=
JP2006518375A (ja
Inventor
モナ・ストーレ−ベックダール
ヨーハン・ヘイルボーン
アンダーシュ・カールソン
コニー・ブーゲントフト
Original Assignee
リポペプチド・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20290232&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP4750690(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by リポペプチド・アクチエボラーグ filed Critical リポペプチド・アクチエボラーグ
Publication of JP2006518375A publication Critical patent/JP2006518375A/ja
Publication of JP2006518375A5 publication Critical patent/JP2006518375A5/ja
Application granted granted Critical
Publication of JP4750690B2 publication Critical patent/JP4750690B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • C12N5/0629—Keratinocytes; Whole skin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
JP2006502781A 2003-01-29 2004-01-28 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用 Expired - Fee Related JP4750690B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE0300207A SE0300207D0 (sv) 2003-01-29 2003-01-29 New use and composition
SE0300207-8 2003-01-29
US44496403P 2003-02-05 2003-02-05
US60/444,964 2003-02-05
PCT/SE2004/000111 WO2004067025A1 (en) 2003-01-29 2004-01-28 Use of the cathelicidin ll-37 and derivatives thereof for wound healing

Publications (3)

Publication Number Publication Date
JP2006518375A JP2006518375A (ja) 2006-08-10
JP2006518375A5 JP2006518375A5 (https=) 2007-03-01
JP4750690B2 true JP4750690B2 (ja) 2011-08-17

Family

ID=20290232

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006502781A Expired - Fee Related JP4750690B2 (ja) 2003-01-29 2004-01-28 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用

Country Status (13)

Country Link
US (5) US7452864B2 (https=)
EP (1) EP1589987B1 (https=)
JP (1) JP4750690B2 (https=)
CN (3) CN1744913B (https=)
CA (1) CA2513598C (https=)
CY (1) CY1115142T1 (https=)
DK (1) DK1589987T3 (https=)
ES (1) ES2467090T3 (https=)
PT (1) PT1589987E (https=)
SE (1) SE0300207D0 (https=)
SI (1) SI1589987T1 (https=)
WO (1) WO2004067025A1 (https=)
ZA (1) ZA200505830B (https=)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060258562A1 (en) * 2000-07-31 2006-11-16 Healor Ltd. Methods and pharmaceutical compositions for healing wounds
SE0300207D0 (sv) * 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
WO2004098536A2 (en) * 2003-03-06 2004-11-18 The Regents Of The University Of California Anti-viral activity of cathelicidin peptides
PT3100611T (pt) 2003-08-01 2018-12-14 Stratatech Corp Equivalentes de pele humana que expressam polipéptidos exógenos
WO2005013885A2 (en) 2003-08-07 2005-02-17 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
US7776823B2 (en) * 2003-10-21 2010-08-17 The Regents Of The University Of California Human cathelicidin antimicrobial peptides
SE0401942D0 (sv) * 2004-07-28 2004-07-28 Lipopeptide Ab New antimicrobial peptide complexes
WO2006067402A2 (en) * 2004-12-22 2006-06-29 Lipopeptide Ab Agents inibiting the cathelin-like protein cap18/ll-37
ES2462541T3 (es) * 2005-06-09 2014-05-23 Meda Ab Método y composición para el tratamiento de trastornos inflamatorios
US9044438B2 (en) 2005-06-17 2015-06-02 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
US8202835B2 (en) 2005-06-17 2012-06-19 Yitzchak Hillman Disease treatment via antimicrobial peptides or their inhibitors
EP2462944A3 (en) 2005-08-29 2012-09-12 HealOr Ltd. Methods and compositions for prevention and treatment of diabetic and aged skin
AU2007262776A1 (en) * 2006-06-20 2007-12-27 Lipopeptide Ab Use cathelicidin antimicrobial protein (hCAP18 ) as anticancer agent
US20100273748A1 (en) * 2006-09-08 2010-10-28 The Regents Of The University Of California Antimicrobial therapy
EP2069377A4 (en) * 2006-09-27 2009-11-11 Univ California METHOD AND COMPOSITIONS FOR THE TREATMENT OF SKIN DISEASES AND SKIN FUNCTIONAL DISORDERS
WO2008103751A2 (en) * 2007-02-20 2008-08-28 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
CN101720237A (zh) * 2007-06-25 2010-06-02 利波佩普蒂德有限公司 新型医用产品
JP2010533705A (ja) * 2007-07-15 2010-10-28 ヒルマン，イチャク 抗菌ペプチドまたはその阻害剤を用いた疾病治療
CN102755649A (zh) * 2007-07-30 2012-10-31 希尔洛有限公司 药物组合物及相关方法
US20100310514A1 (en) * 2009-06-04 2010-12-09 Chi Hin Cho Anti-Inflammatory Bacteria
US20130079382A1 (en) 2009-10-12 2013-03-28 Larry J. Smith Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro
AU2010316006B2 (en) * 2009-11-03 2013-09-26 Lipidor Ab Composition for promoting wound healing
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
WO2012150890A1 (en) * 2011-05-02 2012-11-08 Lipidor Ab Antibacterial composition
AU2013235692B2 (en) * 2012-03-20 2016-12-08 Helix Biomedix Inc Short antimicrobial lipopeptides
US8969290B2 (en) 2012-06-26 2015-03-03 Worcester Polytechnic Institute Matrix scaffold with antimicrobial activity
EP2821077A1 (en) * 2013-07-04 2015-01-07 Praxis Biopharma Research Institute Lipid nanoparticles for wound healing
CN104513293A (zh) * 2013-09-26 2015-04-15 深圳信立泰药业股份有限公司 一种多肽疫苗的盐及其制备方法和含有该盐的药物制品
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
CN103920137B (zh) * 2014-04-28 2016-03-30 中国药科大学 一种具有抗耐药性革兰阳性细菌作用的药物组合物
US10138282B2 (en) * 2014-05-27 2018-11-27 Indiana University Research And Technology Corporation Peptide antagonist of LL-37
CN104984321A (zh) * 2015-07-24 2015-10-21 中国药科大学 人源抗菌肽ll-37在制备治疗或预防血栓性疾病药物中的应用
CN105859867A (zh) * 2016-05-30 2016-08-17 黄石市中心医院 一种人源抗菌肽ll-37突变体及其应用
CN106519042A (zh) * 2016-12-29 2017-03-22 陕西慧康生物科技有限责任公司 人源胶原蛋白与抗菌肽的融合蛋白及其制备方法与编码基因
US20190300575A1 (en) 2018-03-29 2019-10-03 Deetex, LLC Lytic peptide biosensor and methods of making and using the same
CN108659102B (zh) * 2018-04-25 2021-08-17 南方医科大学 具有抗菌及抗炎活性的多肽化合物
ES2799098B2 (es) 2019-06-10 2021-12-10 Univ Madrid Carlos Iii Aptameros agonistas del receptor fpr2 y usos de los mismos
KR102475936B1 (ko) * 2020-10-15 2022-12-09 코스맥스 주식회사 펩타이드 ll-37을 발현하는 효모를 포함하는 화장료 조성물
PL443243A1 (pl) * 2022-12-22 2024-06-24 Uniwersytet Warszawski Nowe peptydy antydrobnoustrojowe
CN118895244B (zh) * 2024-07-23 2025-06-20 浙江自贸区中航生物科技有限责任公司 一种提高nk细胞杀伤活性的多肽及其应用
CN120789277A (zh) * 2025-09-18 2025-10-17 山东大学 一种基于(1,3)-β-D-葡聚糖合成酶抑制剂的抗真菌药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861478A (en) 1987-07-06 1999-01-19 Helix Biomedix, Inc. Lytic peptides
FI963066A7 (fi) 1994-02-04 1996-09-30 Lipocore Holding Ab Lipofiiliset kantoainevalmisteet
ES2183865T3 (es) 1994-02-04 2003-04-01 Lipocore Holding Ab Preparaciones de doble capa de galactolipido que contienen digalactosildiacilglicerol.
BR9506681A (pt) 1994-02-04 1997-11-18 Scotia Lipidteknik Ab Emulsão oleo em água e composição farmacêutica
SE9403055L (sv) 1994-09-13 1996-03-14 Hans G Boman Nytt humant peptidantibiotikum (fall-39) och dess användning
US5654273A (en) * 1994-09-22 1997-08-05 Children's Medical Center Corporation Synducin mediated modulation of tissue repair
EP0935965A4 (en) * 1996-04-23 2002-01-23 Toray Industries SUBSTANCE AGAINST PYLORI
SE515982C2 (sv) * 1998-03-06 2001-11-05 Lipocore Holding Ab Användning av en olja-i-vatten emulsion som bärare för framställning av en topikal kräm eller lotion
US5925534A (en) * 1998-06-08 1999-07-20 Wako Pure Chemical Industries, Ltd. Method for measuring LDL-cholesterol
WO2000057895A1 (en) * 1999-03-26 2000-10-05 Beth Israel Deaconess Medical Center Method for pr-39 peptide regulated stimulation of angiogenesis
AU2001287628A1 (en) 2000-07-17 2002-01-30 Hansa Medical Ab Antimicrobial agent
US8030537B1 (en) 2000-07-27 2011-10-04 Apogene Gmbh & Co. Kg Somatic cloning gene transfer for the production of recombinant proteins, cells and organs
US20020072495A1 (en) * 2000-09-21 2002-06-13 Oleg Chertov LL-37 is an immunostimulant
US6835713B2 (en) * 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
US20030022829A1 (en) * 2001-03-30 2003-01-30 Wendy Maury Novel antiviral activities primate theta defensins and mammalian cathelicidins
EP1358888A1 (en) * 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
GB0223655D0 (en) * 2002-10-10 2002-11-20 Mabtech Ab Method of diagnosis
AU2003288507A1 (en) 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002095076A2 (en) * 2001-05-23 2002-11-28 Kabushiki Kaisha Toyota Chuo Kenkyusho Modified polypeptides having protease-resistance and/or protease-sensitivity

Also Published As

Publication number Publication date
US8936807B2 (en) 2015-01-20
CA2513598C (en) 2015-04-21
US20090088382A1 (en) 2009-04-02
EP1589987A1 (en) 2005-11-02
US9125875B2 (en) 2015-09-08
US20150094256A1 (en) 2015-04-02
CN105079784A (zh) 2015-11-25
EP1589987B1 (en) 2014-04-23
CN1744913B (zh) 2010-05-26
PT1589987E (pt) 2014-05-28
WO2004067025A1 (en) 2004-08-12
CN105079784B (zh) 2018-05-18
US7452864B2 (en) 2008-11-18
CA2513598A1 (en) 2004-08-12
CN1744913A (zh) 2006-03-08
HK1217661A1 (zh) 2017-01-20
US8012933B2 (en) 2011-09-06
ZA200505830B (en) 2006-04-26
US20070149448A1 (en) 2007-06-28
DK1589987T3 (da) 2014-05-26
US8506994B2 (en) 2013-08-13
JP2006518375A (ja) 2006-08-10
SI1589987T1 (sl) 2014-07-31
ES2467090T3 (es) 2014-06-11
US20130287839A1 (en) 2013-10-31
CY1115142T1 (el) 2016-12-14
SE0300207D0 (sv) 2003-01-29
CN101838326A (zh) 2010-09-22
US20110293707A1 (en) 2011-12-01

Similar Documents

Publication Publication Date Title
JP4750690B2 (ja) 創傷治癒のための、カテリシジンｌｌ−３７、および、それらの誘導体の使用
Heilborn et al. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium
AU2006294581B2 (en) Amniotic membrane preparations and purified compositions and methods of use
CA2032059C (en) Wound treatment employing biologically active peptides
TW201309724A (zh) 色素上皮衍生因子衍生之多胜肽於促進幹細胞增殖與傷口癒合之用途
US20040037781A1 (en) Peptides with antioxidant and antimicrobial properties
US20080207515A1 (en) Promotion of Epithelial Regeneration
CZ2001538A3 (cs) Peptidy odvozené od TNF pro použití v léčbě otoků
WO2010104696A1 (en) Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
US6984622B2 (en) Use of lipopolysaccharides to manage corneal infections and wounds
HK1217661B (en) Use of the cathelicidin ll-37 and derivatives thereof for wound healing
HK1148756A (en) Use of the cathelicidin ll-37 and derivatives thereof for wound healing
KR20030013189A (ko) 파골세포 분화를 억제하는 펩타이드 ｐ1
US20230002448A1 (en) Collagen production
ANDERSON Antimicrobial peptides of vertebrates

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061226

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100312

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100615

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110426

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110519

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 4750690

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140527

Year of fee payment: 3

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees